Trastuzumab emtansine
- Generic Name
- Trastuzumab emtansine
- Brand Names
- Kadcyla
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1018448-65-1
- Unique Ingredient Identifier
- SE2KH7T06F
- Background
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine deriva...
- Indication
Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
- Associated Conditions
- HER2-Positive Early Stage Breast Cancer, HER2-positive, Metastatic Breast Cancer
- Associated Therapies
- -
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
- Conditions
- Interventions
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 208
- Registration Number
- NCT01835236
- Locations
- 🇨🇭
Hirslanden Klinik Aarau, Aarau, Switzerland
🇨🇭Kantonspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Baden, Baden, Switzerland
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1487
- Registration Number
- NCT01772472
- Locations
- 🇺🇸
Kaiser Permanente - Vallejo, Vallejo, California, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Kaiser Permanente - San Diego, San Diego, California, United States
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 380
- Registration Number
- NCT01745965
- Locations
- 🇩🇪
Breast Center of the University of Munich (LMU), Munich, Germany
🇩🇪Ev. Krankenhaus Bethesda Brustzentrum Niederrhien, Mönchengladbach, Germany
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2185
- Registration Number
- NCT01702571
- Locations
- 🇦🇺
Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research, North Sydney, New South Wales, Australia
🇦🇷CEMIC, Buenos Aires, Argentina
🇧🇪CHU Sart-Tilman, Liège, Belgium
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 415
- Registration Number
- NCT01641939
- Locations
- 🇬🇹
Centro Oncológico Sixtino / Centro Oncológico SA, Guatemala, Guatemala
🇲🇽Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico
🇲🇽Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre, Chihuahua, Mexico
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 90
- Registration Number
- NCT01565200
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇳🇱Vrije Universiteit Amsterdam (VUMC), Amsterdam, Netherlands
🇧🇪Universitair Ziekenhuis Antwerpen (UZA), Antwerpen, Edegem, Belgium
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT01513083
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 140
- Registration Number
- NCT01494662
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸UPMC Passavant Cranberry, Cranberry Township, Pennsylvania, United States
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
- Conditions
- Interventions
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 602
- Registration Number
- NCT01419197
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT01196052
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.